IBD

Lilly's Omvoh scores second IBD win with FDA nod in Crohn's
First Word Pharma
Wed, 01/15/25 - 11:50 pm
Eli Lilly
Omvoh
IBD
FDA
Crohn's Disease
10 clinical trials to watch in the first half of 2025
BioPharma Dive
Thu, 01/2/25 - 11:42 am
clinical trials
Eli Lilly
cardiovascular disease
Arvinas
protein degradation
Vera Therapeutics
IgA nephropathy
Novarts
pelacarsen
Entyvio
IBD
Novo Nordisk
Alzheimer's disease
Beam Therapeutics
sickle cell disease
COMPASS Pathways
psychedelics
Moderna Therapeutics
Verve Therapeutics
high cholesterol
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
BioPharma Dive
Tue, 12/17/24 - 11:59 am
Sanofi
Teva Pharmaceutical
IBD
Merck
Roche
duvakitug
A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill
Pharma Voice
Thu, 07/18/24 - 11:12 am
Ensho Therapeutics
IBD
Gilead Sciences
Eli Lilly
Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster
Fierce Biotech
Mon, 07/8/24 - 11:54 am
Eli Lilly
Morphic
M&A
Takeda
Entyvio
IBD
AbbVie inks immune disorder drug licensing deal with China's FutureGen
Reuters
Thu, 06/13/24 - 11:07 am
AbbVie
FutureGen
China
IBD
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Motley Fool
Sun, 10/29/23 - 08:44 pm
Roche
Eli Lilly
Pfizer
IBD
ulcerative colitis
Crohn's Disease
mirikizumab
Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate
BioSpace
Mon, 10/23/23 - 10:35 am
Roche
M&A
Televant
Roivant
RVT-3101
IBD
ulcerative colitis
Crohn’s disease
Sanofi pays Teva $500M to join Merck, Roivant in red-hot bowel disease race
Fierce Biotech
Wed, 10/4/23 - 09:48 am
Sanofi
Teva Pharmaceutical
inflammatory bowl disease
IBD
Merck
Roivant
Celltrion presents infliximab data at ECCO Congress
Clinical Trials Arena
Wed, 07/5/23 - 10:26 am
Celltrion
ECCO
infliximab
IBD
AstraZeneca Teams Up With Startup Quell in Type 1 Diabetes, IBD Cell Therapy Pact
MedCity News
Fri, 06/9/23 - 11:52 am
AstraZeneca
Quell Therapeutics
type 1 diabetes
IBD
cell therapy
AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral
Fierce Biotech
Thu, 06/1/23 - 11:41 am
AstraZeneca
IBD
AbbVie
JNJ
brazikumab
Skyrizi
Stelara
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Motley Fool
Mon, 04/24/23 - 10:18 am
Pfizer
Roivant
IBD
RVT-3101
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
BioPharma Dive
Sun, 04/16/23 - 11:31 pm
Merck
M&A
Prometheus Biosciences
IBD
FDA declines to approve Eli Lilly's bowel disease drug
Yahoo/Reuters
Thu, 04/13/23 - 10:19 pm
Eli Lilly
IBD
FDA
mirikizumab
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
Fierce Pharma
Thu, 03/23/23 - 11:39 am
AbbVie
Skyrizi
IBD
ulcerative colitis
clinical trials
Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
Biopharma Dive
Mon, 01/23/23 - 09:45 pm
Roivant Sciences
IBD
Pfizer
Matt Gline
hub-and-spoke
Sanofi and CytoReason target IBD in expanded collaboration
Pharma Live
Mon, 01/23/23 - 11:03 am
Sanofi
CytoReason
IBD
R&D
Satisfai, Virgo, and Alimentiv to boost trials using AI-powered technology
Clinical Trials Arena
Thu, 10/6/22 - 10:55 am
Satisfai Health
Virgo Surgical Video Solutions
Alimentiv
clinical trials
artificial intelligence
IBD
Nestlé wagers $41M on Enterome's preclinical food allergy and IBD prospect
Fierce Biotech
Mon, 07/18/22 - 10:00 am
Nestle
Enterome
food allergies
IBD

Pages